CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LTRI) in infants and children worldwide and poses a significant concern in Brazil. Palivizumab is covered by Health Insurance Companies for early preterm infants (

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Falavigna, S.F. Watanabe, J. Santoro, K. Ribeiro, N. Schneider, M. Safadi, R.T. Stein, A. Kieffer, A. Tolardo Source Type: research